Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors Academic Article uri icon

Overview

MeSH Major

  • Etoposide
  • Neoplasms
  • Organophosphorus Compounds
  • Prodrugs

abstract

  • Etoposide phosphate displays excellent patient tolerance in conventional dosages when administered as a 5-minute intravenous bolus. The suggested phase II dose is 150 mg/m2 on days 1, 3, and 5. The ability to administer etoposide phosphate as a concentrated, rapid infusion may prove of value both in the outpatient clinic and in high-dose regimens.

publication date

  • September 1994

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 8083713

Additional Document Info

start page

  • 1902

end page

  • 9

volume

  • 12

number

  • 9